text:
|Publication number
|Publication type
|Application number
|Publication date
|Feb 1, 2011
|Filing date
|Jul 7, 2009
|Priority date
|Dec 8, 1997
|Fee status
|Also published as
|Publication number
|Stephen D. Gillies, Kin-Ming Lo, Yan Lan
|Original Assignee
|Merk Patent Gmbh
|Export Citation
|BiBTeX, EndNote, RefMan
|Patent Citations (170), Non-Patent Citations (302), Classifications (23), Legal Events (3)
|External Links: USPTO, USPTO Assignment, Espacenet
This application is a division of U.S. patent application Ser. No. 11/804,895, filed May 21, 2007, issued as U.S. Pat. No. 7,576,193 on Aug. 18, 2009, which is a continuation of U.S. patent application Ser. No. 10/935,532, filed Sep. 7, 2004, issued as U.S. Pat. No. 7,226,998 on Jun. 5, 2007, which is a continuation of U.S. patent application Ser. No. 10/005,212, filed Dec. 4, 2001, issued as U.S. Pat. No. 6,838,260 on Jan. 4, 2005, which is a continuation of U.S. patent application Ser. No. 08/986,997, filed Dec. 8, 1997, now abandoned, the contents of each of which are incorporated by reference herein.
The present invention relates generally to fusion proteins. More specifically, the present invention relates to heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation.
One of the key immune regulators is the T helper cell which reacts to antigens presented on HLA class II molecules. This CD4+ cell differentiates in response to antigenic stimulation and becomes a type 1 or type 2 helper (Th1 or Th2) according to the type of cytokines that it secretes. Mosmann and Coffman. Ann. Rev. Immunol. 7:145-173 (1989). A Th1 response leads to the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ) which stimulates cell-mediated immune reactions against intracellular pathogens. A Th2 response leads to the secretion of IL-4, IL-5 and IL-10 which stimulates antibody responses to extracellular pathogens. The most interesting component of this system of regulation is that one response inhibits the other through the negative regulator activities of the cytokines that are produced. Thus, IL-4 and IL-10 can down-regulate Th1 responses while IFN-γ can down-regulate Th2 responses.
The regulatory activity of T helper cells and their differentiation following exposure to antigen is regulated by cytokines as well. IL-12, a disulfide-linked heterodimeric cytokine with a 40 kDa subunit and 35 kDa subunit, exerts a powerful positive regulatory influence on the development of Th1 helper T-cell immune responses. See review by Trinchieri, Blood 84: 4008-4027 (1994). IL-12 also has a powerful synergistic effect in the induction of IFN-γ from both T helpers and natural killer (NK) cells (Eur. Patent Appl. 90123670.3). Secreted IFN-γ then inhibits any Th2 cell proliferation and polarizes the response to favor cell-mediated immunity.
One way of changing the outcome of an immune response would be to administer the appropriate cytokine at the time of antigen stimulation. If IL-4 was the major cytokine present during antigen stimulation, the Th2 response would be enhanced and the Th1 response would be inhibited. In contrast, if IL-12 was the major cytokine present during antigen stimulation, the Th1 response would be enhanced and the Th2 response would be inhibited. However, systemic administration of cytokines is difficult due to their very short circulating half-lives and their deleterious side effects.
A better approach is to target the effect of the cytokine to a cell surface antigen by fusing it to an antibody (or fragment derived therefrom) having specificity and affinity for that antigen. See Gillies, et al., Proc. Natl. Acad. Sci. 89: 1428-1432 (1992); U.S. Pat. No. 5,650,150, the disclosure of which is incorporated herein by reference. Alternatively, the stimulatory cytokine can be linked to a protein antigen via a peptide linkage in the form of a fusion protein. See Hazama, et al., Vaccine 11: 629-636 (1993). However, the complex structure of IL-12 makes it more difficult to express as a fusion protein due to the necessity of expressing exactly the same molar ratio of each subunit in the final product. In fact, IL-12 itself is naturally expressed and secreted as a mixture of p40 homodimer. D'Andrea, et al., J. Exp. Med., 176: 1387-1398 (1992).
Therefore, there is a need in the art for methods of producing fusion proteins with heterodimeric cytokines and an antibody or an antigen that maintain the natural heterodimeric structure of the cytokine and secretes the molecules with equimolar ratios of the subunits.
The present invention provides heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation and methods for producing these heterodimeric fusion proteins. Specifically, the present invention provides methods for the production of fusion proteins with IL-12 that maintain its natural heterodimeric structure, and provide for the secretion of the molecules with equimolar ratios of IL-12 subunits.
In one aspect of the invention, the fusion proteins comprise a heterodimeric cytokine linked to an antibody, or a portion thereof. In a preferred embodiment, the fusion protein comprises two chimeric chains linked by a disulfide bond. Each chimeric chain comprises a different subunit of the heterodimeric cytokine linked through a peptide bond to a portion of an Ig heavy chain.
In an alternative preferred embodiment, the fusion protein comprises a first chimeric chain comprising one of the subunits of the heterodimeric cytokine linked by a peptide bond to a portion of an Ig heavy chain. This subunit is linked by a disulfide bond to the other subunit of the heterodimeric cytokine. In another alternative preferred embodiment, this first chimeric chain is linked by a disulfide bond to a second chimeric chain comprising one of the subunits of the heterodimeric cytokine linked by a peptide bond to a portion of an Ig heavy chain and by a disulfide bond to the other subunit of the heterodimeric cytokine.
In yet another alternative preferred embodiment, the fusion protein is a trimeric fusion protein comprising a first and a second chimeric chain linked by a disulfide bond. Each chimeric chain comprises a subunit of the heterodimeric cytokine linked by a peptide bond to a portion of an Ig heavy chain. The subunit of one of the chimeric chains is further linked by a disulfide bond to a different subunit of the heterodimeric cytokine.
Fusion proteins of the invention may be considered chimeric by virtue of two aspects of their structure. First, the fusion protein is chimeric in that it includes an immunoglobulin chain (typically but not exclusively a heavy chain) of appropriate antigen-binding specificity fused to a given heterodimeric cytokine. Second, an immunoconjugate of the invention may be chimeric in the sense that it includes a variable region and a constant region which may be the constant region normally associated with the variable region, or a different one and thus a V/C chimera; e.g., variable and constant regions from different species. Also embraced within the term "fusion protein" are constructs having a binding domain comprising framework regions and variable regions (i.e., complementarity determining regions) from different species, such as are disclosed by Winter, et al., GB2, 188, 638.
The heterodimeric cytokine-antibody fusion protein of the present invention preferably displays antigen-binding specificity. In a preferred embodiment, the heterodimeric cytokine-antibody fusion protein comprises a heavy chain. The heavy chain can include a CH1, CH2, and/or CH3 domains. In an alternative preferred embodiment, the heterodimeric cytokine-antibody fusion protein comprises a light chain. The invention thus provides fusion proteins in which the antigen binding specificity and activity of an antibody are combined with the potent biological activity of a heterodimeric cytokine. A fusion protein of the present invention can be used to deliver selectively a heterodimeric cytokine to a target cell in vivo so that the heterodimeric cytokine can exert a localized biological effect.
Preferably, the fusion protein of the present invention displays cytokine biological activity. The preferred heterodimeric cytokine of the fusion protein is IL-12. Fusions with antibodies capable of binding antigens are useful for co-localizing the immune stimulatory activity of IL-12 either to target cells or target protein antigens.
Further, the fusion protein of the present invention preferably has a longer circulating half-life than an unlinked heterodimeric cytokine. Fusions with the Fc portion of antibodies and IL-12 are useful for altering the pharmacology and biodistribution of the molecule by increasing its circulating half-life and its affinity for Fc-receptor bearing cells, e.g. antigen presenting cells. Changes in biodistribution may also alter its systemic toxicity by changing the mechanism by which it is cleared from the circulation.
In another aspect of the invention, the fusion proteins comprise a heterodimeric cytokine linked to an antigen. The preferred heterodimeric cytokine-antigen fusion protein of the present invention displays cytokine biological activity and antigenic activity. Further, the fusion protein of the present invention preferably has a longer circulating half-life than an unlinked heterodimeric cytokine. The preferred heterodimeric cytokine of the fusion protein is IL-12.
In a preferred embodiment, the fusion protein comprises two chimeric chains linked by a disulfide bond. Each chimeric chain comprises a different subunit of the heterodimeric cytokine, either of which is linked through a peptide bond to an antigen.
In an alternative preferred embodiment, the fusion protein comprises a first chimeric chain comprising one of the subunits of the heterodimeric cytokine linked by a peptide bond to an antigen. This subunit is linked by a disulfide bond to the other subunit of the heterodimeric cytokine. In another alternative preferred embodiment, this first chimeric chain is linked by a disulfide bond to a second chimeric chain comprising one of the subunits of the heterodimeric cytokine linked by a peptide bond to an antigen and by a disulfide bond to the other subunit of the heterodimeric cytokine.
In another alternative preferred embodiment, the fusion protein is a trimeric fusion protein comprising a first and a second chimeric chain linked by a disulfide bond. Each chimeric chain comprises a subunit of the heterodimeric cytokine linked by a peptide bond to an antigen. The subunit of one of the chimeric chain is further linked by a disulfide bond to a different subunit of the heterodimeric cytokine.
The invention also features DNA constructs encoding the above-described fusion proteins, and cell lines, e.g., myelomas, transfected with these constructs.
The invention also includes a method for selectively targeting a heterodimeric cytokine. In a preferred embodiment, the method comprise linking at least one subunit of a heterodimeric cytokine by a peptide bond to a portion of an Ig heavy chain. In an alternative preferred embodiment, the method comprise linking each of the two subunits of a heterodimeric cytokine by a peptide bond to a portion of an Ig heavy chain, thereby forming two chimeric chain. The two chimeric chains are linked by a disulfide bond, thereby forming a heterodimeric fusion protein. In yet another preferred embodiment, the method comprises (1) linking one of the two subunits of a first heterodimeric cytokine by a peptide bond to an Ig heavy chain, thereby forming a first chimeric chain; (2) linking one of the two subunits of a second heterodimeric cytokine by a peptide bond to an Ig heavy chain, thereby forming a second chimeric chain; and (3) linking the first and second chimeric chains by a disulfide bond, thereby forming a fusion protein. The resulting fusion proteins can display binding specificity for a predetermined antigen and cytokine biological activity.
The invention also includes a method of selectively delivering a heterodimeric cytokine to a target cell. The method includes providing a heterodimeric cytokine fusion protein including a chimeric Ig chain including an Ig heavy chain having a variable region specific for an epitope on the target cell and a constant region joined at its carboxy terminus by a peptide bond to a cytokine, and an Ig light chain combined with the chimeric Ig heavy chain, forming a functional antigen-binding site, and administering the fusion protein in an amount sufficient to reach the target cell to a subject harboring the target cell.
Further, the invention features a method of increasing the circulating half-life of a heterodimeric cytokine. In a preferred embodiment, the method comprise linking at least one subunit of a heterodimeric cytokine by a peptide bond to a polypeptide. In an alternative preferred embodiment, the method comprises linking each of the two subunits of a heterodimeric cytokine by a peptide bond to a polypeptide, thereby forming two chimeric chain. The two chimeric chains are linked by a disulfide bond, thereby forming a heterodimeric fusion protein. In yet another preferred embodiment, the method comprises (1) linking one of the two subunits of a first heterodimeric cytokine by a peptide bond to a polypeptide, thereby forming a first chimeric chain; (2) linking one of the two subunits of a second heterodimeric cytokine by a peptide bond to a polypeptide, thereby forming a second chimeric chain; and (3) linking the first and second chimeric by a disulfide bond, thereby forming a fusion protein. The polypeptide can be serum albumin, an antigen, and a portion of an Ig heavy chain. The resulting fusion proteins display cytokine biological activity.
The IL-12 fusion proteins of the present invention are useful for specific targeting or immune stimulation when it is important to generate a cell-mediated immune response, such as in cancer immunotherapy or antiviral responses. They are also useful for specifically downregulating Th2 responses which often lead to the overproduction of IL-4. This cytokine has been shown to be essential for the development of allergy through the induction of a Th2 response and the resulting overproduction of IgE antibody.
The foregoing and other objects of the present invention, and the various features thereof, may be more fully understood from the following description, when read together with the accompanying drawings, in which:
The present invention describes fusion proteins between heterodimeric cytokines and other proteins. Heterodimeric cytokines can be fused to, for example, proteins with targeting or antigenic properties. Fusion proteins between heterodimeric cytokines and proteins with targeting or antigenic properties may have a longer circulating half life than unlinked heterodimeric cytokines. Targeting or antigenic properties are not required for the increased circulating half life as this property can also be achieved by fusing a heterodimeric cytokine with a protein that lacks targeting or antigenic properties such as, for example, serum albumin.
The fusion proteins of this invention can be produced by genetic engineering techniques. As depicted in
At present, the only known heterodimeric cytokine is IL-12. However, as novel heterodimeric cytokines are identified and sequenced, a skilled artisan will be able to use methods of the present invention to produce fusion proteins with these novel heterodimeric cytokines.
Methods for synthesizing useful embodiments of the invention are described, as well as assays useful for testing their pharmacological activities, both in vitro and in pre-clinical in vivo animal models. The preferred gene construct encoding a chimeric chain (i.e., a subunit of the heterodimeric cytokine fused to a polypeptide) includes, in 5′ to 3′ orientation, a DNA segment which encodes a polypeptide and DNA coding for one subunit of the heterodimeric cytokine. An alternative preferred gene construct includes, in 5′ to 3′ orientation, a DNA segment which encodes one subunit of the heterodimeric cytokine and DNA coding for a polypeptide. The fused gene is assembled in or inserted into an expression vector for transfection of the appropriate recipient cells where it is expressed.
The invention is illustrated further by the following non-limiting examples:
Human peripheral blood monocytes (PBMC) were obtained from a healthy volunteer and were purified by centrifugation on a Ficoll-Hypaque (Pharmacia) gradient (1700 rpm for 20 nm). The "buffy" coat containing the PBMC was diluted with serum-free culture medium (SF-RPMI) to a volume of 50 ml and collected by centrifugation at 1500 rpm for 5 min. Cells were resuspended in AIM-V cell culture medium (GIBCO) at a density of 5�106 cells/ml and were cultured for 2 days at 37� C. in a humidified CO2 incubator. The attached cells were selected by gently agitating the culture flask to remove non-adherent cells. Fresh medium containing phorbol ester (100 nM) and the calcium ionophore, ionomycin (0.1 μg/ml) was added. After three days, the cells were collected by gentle scraping and centrifugation. Poly A+ mRNA wvas prepared using oligo dT-coated beads (Dynal, Inc.).
Subunit cDNAs were cloned using polymerase chain reactions (PCR). First strand cDNA was synthesized in a 50 μl reaction containing oligo dT primer (50 μg/ml), reaction buffer, RNAsin (10 U/ml) and reverse transcriptase. Incubation was at 43� C. for 2 hrs, followed by extraction with phenol, phenol:chloroform (50:50) and precipitation with ethanol. The cDNA product was used as template for PCR reactions containing Taq polymerase and reaction buffer (10� buffer; Perkin Elmer), sense and antisense primers (0.2 to 0.5 μM each), and 10% of the cDNA reaction. Primer sequences were 5′-CCAGAAAGCAAGAGACCAGAG-3′ (SEQ ID NO: 1) for the sense primer, and 5′-GGAGGGACCTCGAGTTTTAGGAAGCATTCAG-3′ (SEQ ID NO: 2) for the antisense primer of the p35 subunit cDNA. The sense primer is derived from a sequence in the 5′ untranslated region of the p35 message just upstream of a XmaI site, while the antisense primer encodes a translational stop codon followed shortly thereafter by a convenient XhoI site for directional subcloning in an expression vector. The primers for the p40 subunit cDNA were 5′-CTCCGTCCTGTCTAGAGCAAGATGTGTC-3′ (SEQ ID NO: 3) for the sense and 5′-GCTTCTCGAGAACCTAACTGCAGGGCACAG-3′ (SEQ ID NO: 4) for the antisense primer. The sense primer encodes a unique XbaI site upstream of the translation start site while the antisense primer encodes a stop codon and unique XhoI site as above. Both subunit sequences, cloned with these PCR primers, will be expressed as single proteins and thus require native (or other) secretory leader sequences for proper heterodimer assembly and secretion. PCR reactions consisted of 40 cycles including: 1 min at 92� C., 2 min at 52� C., and 3 min at 72� C., following an initial denaturation step at 94� C. for 2 min. Products were gel purified and cloned in the SK cloning vector (Strategene) for sequence verification. DNA sequencing using a commercial kit (U.S. Biochemical) was carried out on each of the subunit cDNA. The same procedure can be used to clone the mouse p35 subunit cDNA from spleen cells activated with Concanavalin A (5 μg/ml in culture medium for 3 days). Recommended primers are 5′-CCTCTACTAACATGTGTCAATCACGCTACCTC-3′ (SEQ ID NO: 5) for the sense and 5′-CCCTCGAGTCAGGCGGAGCTCAGATAGCC-3′ (SEQ ID NO: 6) for the antisense primers encoding the same restriction sites as described above for the human p35 subunit.
In order to make the fused versions of each subunit, the DNAs encoding the mature protein sequence of each were adapted as follows. The p40 subunit DNA was digested with NdeI which cuts very close to the junction of the mature protein and leader sequence, and XhoI. An adapter oligonucleotide was synthesized with the sequence 5′-CCGGGCAAGTCCA-3′ (SEQ ID NO: 7) hybridized to a second, partly complementary oligonucleotide with the sequence 5′-TATGGACTTGC-3′ (SEQ ID NO: 8). The double stranded DNA contains overhanging sequence compatible with ligation to an XmaI site at the 5′ end and an NdeI site at the 3′ end. This fragment was ligated to the NdeI-XhoI fragment of the p40 cDNA and cloned as an XmaI to XhoI fragment in vector pdC-Fc-X, cut with XmaI and XhoI. This vector already contains a human IgG1 Fc encoding DNA fragment in its genomic configuration (containing introns and exons) and fused downstream of a leader sequence derived from a mouse light chain. See, Gillies, et al., J. Immunol. Methods 125: 191-202 (1989). The addition of a DNA fragment to its unique XmaI site allows for the production of fusion proteins joined directly to the carboxyl terminus of the Fc, provided that the reading frame between the two sequences is maintained (Lo, et al., U.S. Pat. No. 5,541,087). Other proteins (e.g., antigen, serum albumin) can be fused to the amino termini of these subunits in the same manner. The advantages of this method include the large quantities of product produced and the ease of purification of the product by binding to and elution from protein A Sepharose.
The same general strategy was used to fuse the p35 subunit DNA to human Fc. In this case, a XmaI-BalI linker was synthesized using the oligonucleotides 5′-CCGGGAAGAAACCTCCCCGTGG-3′ (SEQ ID NO: 9) and 5′-CCACGGGGAGGTTTCTTC-3′ (SEQ ID NO: 10), which were ligated to a p35 subunit DNA, cut with Ball and XhoI, and subcloned as an XmaI-XhoI fragment in the pdC-Fc-X vector, as described above. The human p35 subunit has been shown to be active for human cells but not mouse cells, in terms of IL-12 activity, whereas the human p40 subunit does not show species specificity. Therefore, the human p40 subunit can be used to make either all human IL-12 fusion proteins or hybrid human/mouse fusion proteins.
The resulting constructs encode Fc-p35 or Fc-p40 fusion proteins which are expected to spontaneously dimerize into proteins of 120 kD (50 Kd from the Fc) and 130 kD respectively and to migrate after reduction on denaturing SDS gels as proteins of 60 kD and 65 kD. The individual subunit cDNAs were subcloned in the pdC expression vector (without the Fc) for their expression as independent proteins. This vector provides promoter sequences for expression of mRNA, transcribed from the cDNA insert, following the transfection of mammalian cells. It also provides for a 3′ untranslated region and poly A addition site, downstream of the 3′ XhoI insertion site. There are also sequences necessary for the propagation of the plasmid in E. coli and selection with ampicillin, as well as a selectable marker gene, such as dihydrofolate reductase (dhfr), for conferring resistance to methotrexate. These same components are also used in the pdC-Fc-X vector for expression of the fusion proteins.
For expression of biologically-active IL-12 fusion protein heterodimers, different combinations of the individual vectors encoding fusion and non-fusion forms of the subunits were transiently expressed by co-transfection of human 293 epidermal carcinoma cells. DNA was purified using preparative kits (Wizard, Promega Inc.), ethanol precipitated for sterilization and resuspension in sterile water. Calcium phosphate precipitates were prepared by standard methods using 10 μg of DNA per ml (5 μg of each when two plasmids were co-transfected) and 0.5 ml/plate were added to cultures of 293 growing in 60 mm plates at approximately 70% confluency. M
An example of an analysis of the co-expression of various fusion proteins and individually expressed proteins, under reducing conditions, is show in
Biological activity was measured in an IFN-γ induction assay using mitogen-activated human PBMC, purified as described in Example 1. After gradient centrifugation, cells were resuspended in cell culture medium containing 10% fetal bovine serum (RPMI-10) and phytohemaglutinin (PHA; 10 μg/ml) at a density of 5�106 cells/ml and were cultured for 3 days at 37� C. in a humidified CO2 incubator. The PHA-activated cells were collected by centrifugation, washed three times with an equal volume of SF-RPMI and resuspended in fresh RPMI-10 (1�106 cells/ml). Aliquots (100 μl) were dispensed into the wells of multiple 96-well plates to give a final cell number of 105 per well. Test samples from culture medium were serially diluted in fresh culture medium and added to wells of the 96-well plate Stimulation medium (50 μl/well) containing 10% serum and IL-2 (25 U/ml) was added. Control wells received only IL-2 (negative control) or both IL-2 and commercial IL-12 (R & D Systems) but no sample (positive control). The plates were incubated for 48 hr at 37� C. in a CO2 incubator at which time aliquots (20 μl) were removed for analysis of IFN-γ concentration by ELISA.
The same assay was used to determine the activity of mouse forms of IL-12 fusion proteins, except that spleen cells from Balb/c mice activated for 3 days with Concanavalin A, were used instead of PHA-activated human PBMC. A mouse-specific ELISA was used to quantitate the amount of IFN-γ induced by the human p40/mouse p35 hybrid molecules from mouse cells.
For the human system, a quantitative ELISA was developed by coating 96-well plates (Nunc-Immuno plate F96 Cert. Maxisorb) with a mouse monoclonal antibody against human IFN-γ (1 μg/ml) in phosphate buffered saline (PBS; Pestka Biological Laboratories) overnight at 4� C., washing unbound antibody three times with PBS, and blocking with a solution of 1% bovine serum albumin (BSA) and 1% goat serum in PBS (150 μl/well for 2 hr at 37� C.). After washing the blocked plates four times with PBS, test samples and dilutions of the IFN-γ standard were added in a final volume of 100 μl/well. Following an overnight incubation at 4� C., the plates were washed four times with PBS, and a polyclonal rabbit antiserum against human IFN-γ (1/10000 dilution; Petska Biological Laboratories) was added. After an additional incubation for 1 hr at 37� C. and four washes with PBS, a polyclonal donkey anti-rabbit detecting antibody, conjugated to horse radish peroxidase (1/700 dilution; Petska Biological Laboratories) was added for 1 hr at 37� C. The plates are then washed four times with PBS and 100 μl of K-blue substrate (ELISA Technologies, Neogen Corp.) was added until the color in the wells containing the standard curve was sufficiently developed, at which time 100 μl of Red-stop solution (ELISA Technologies) was added. The plate was read at 650 nm using an ELISA plate reader (Dynatech MR7000) and the amount of IFN-γ was calculated by comparing the optical density of the test sample with a standard curve derived from the dilutions of the control IFN-γ. The amount of IFN-γ that was induced in the presence of both IL-2 and IL-12 generally ranges from 1200-2000 pg/ml while the amount produced in the absence of IL-12 was generally less than 50 pg/ml.
The biological activity of the culture supernatants described in Example 2 were compared for their ability to stimulate IFN-γ production. As depicted in
The experiments described in Example 2 demonstrate that a convenient way to express fusion proteins with the IL-12 heterodimeric cytokine is to co-express a fused p35 subunit protein together With the free p40 subunit in the same cell. This can be done by two approaches: the first is achieved by co-transfecting the fusion protein vector and the p40 expression vector simultaneously (i.e., simultaneous transfection); the second is to first transfect a cell with p40 alone and select for high level, stable secretors of this protein, and then use this cell as a recipient for transfection by the fusion protein expressing construct (i.e., sequential transfection). The latter method is particularly useful when the fusion protein is an antibody molecule with both a heavy and light chain that need to be assembled properly for correct assembly and secretion. Theoretically, the fusion of p35 subunit could be to the heavy or light chain, but the preferred embodiment would be to the carboxyl terminus of the heavy chain, where it can be more free to interact with the IL-12 receptor on cells. It is also possible to fuse the p35 subunit via its carboxyl terminus to the amino terminus of the heavy or light chain. In this case, a leader sequence would be required for p35 expression, since it would be at the amino terminus of the fusion protein, thus requiring its direction to the endoplasmic reticulum for assembly and secretion from the cell.
The nucleic acid construct can also include the endogenous promoter and enhancer for the variable region-encoding gene to regulate expression of the chimeric immunoglobulin chain. For example, the variable region encoding genes can be obtained as DNA fragments comprising the leader peptide, the VJ gene [functionally rearranged variable (V) regions with joining (J) segment] for the light chain or VDJ gene for heavy chain, and the endogenous promoter and enhancer for these genes. Alternatively, the gene coding for the variable region can be obtained apart from endogenous regulatory elements and used in an expression vector which provides these elements.
Variable region genes can be obtained by standard DNA cloning procedures from cells that produce the desired antibody. Screening of the genomic library for a specific functionally rearranged variable region can be accomplished with the use of appropriate DNA probes such as DNA segments containing the J region DNA sequence and sequences downstream. Identification and confirmation of correct clones are then achieved by DNA sequencing of the cloned genes and comparison of the sequence to the corresponding sequence of the full length, properly spliced mRNA.
4.1 Simultaneous Transfection
Simultaneous transfection can be achieved by constructing a vector with two transcription units and a selectable marker gene. Such vectors are described for the expression of recombinant antibodies in mammalian cells. Gillies, et al., J. Immunol. Methods 125: 191-202 (1989). An alternative method is to use two independent plasmid vectors (one with a transcription unit for the fusion protein and one with a transcription unit for the p40 subunit) with their own selectable marker genes, and to select for successfully transfected, expressing cells by culturing in the presence of the drugs to which the cells have become resistant (e.g., methotrexate in cells transfected with the dhfr gene). Still another approach would be to use an expression vector for the fusion protein to the p35 subunit containing a selectable marker gene and co-transfecting a second vector with no selectable marker gene and a transcription unit for the p40 subunit. Any drug resistant clone obtained by the latter method could not secrete the fusion protein in the absence of the p40 subunit and thus, would not be detected by an ELISA assay of the culture supernatant. Only cells transfected with both vectors would secrete the intact fusion protein-p40 heterodimer.
A plasmid vector (pdHL7-14.18-p35) was constructed, as described in Gillies, et al., J Immunol. Methods 125: 191-202 (1989), that contains a dhfr-selectable marker gene, a transcription unit encoding a humanized 14.18 anti-GD2 antibody light chain, and a transcription unit encoding a humanized heavy chain fused to the p35 subunit of human IL-12. The fusion was achieved by ligation of the XmaI to XhoI fragment of the adapted p35 subunit cDNA, as described in Example 2, to a unique XmaI site at the end of the CH3 exon of the human IgG1 H chain gene. Both the H and L chain transcription units include a cytomegalovirus (CMV) promoter (in place of the metallothionein promoter in the original reference) at the 5′ end and a poly adenylation site at the 3′ end. A similar vector (pC-p40) was constructed for expression of the free p40 subunit but did not include a selectable marker gene (dhfr or other) but still used the CMV promoter for transcription. The coding region in this case included the natural leader sequence of the p40 subunit for proper trafficking to the endoplasmic reticulum and assembly with the fusion protein. Another version of this vector (pNC-p40), which includes the neomycin resistance gene, was constructed for use in sequential transfection.
For simultaneous transfection, plasmid DNAs (approximately 10 μg of each plasmid; pdHL7-14.18-p35 and pC-p40) were linearized by digestion with SalI restriction enzyme, purified using PCR Cleanup kit (Wizard, Promega), and electroporated into 5�106 myeloma cells (in 0.5 ml ice cold PBS) using a setting of 0.25 volts and 500 μF. After a recovery for 10 min on ice, cells were transferred to fresh medium and plated in 96-well dishes at approximately 105 cells/ml. After 48 hr, cells were fed with medium containing methotrexate (0.1 μM). Fresh medium was added by exchange of half the fluid volume every 4 days until clones appeared. Expression of the desired antibody-IL-12 fusion protein was assayed using an ELISA based on antibody Fc detection. The capture antibody reacted with human H and L chains, and the detection utilized an antibody specific for human Fc. Positive clones were expanded in selection medium and the product was purified by binding to and elution from protein A Sepharose as described above Eluted proteins were analyzed by PAGE and detected by staining with Coomassie Blue.
4.2 Sequential Transfection
For sequential transfection, plasmid pNC-p40 was electroporated into cells, as described above, and cells were plated and selected in G418-containing medium. Culture supernatants from drug-resistant clones were tested by ELISA for production of p40 subunit. The capture antibody was a mouse anti-human IL-12 p40 and the detecting antibody was directed to human IL-12 p40/p70. Commercial ELISA kits are available from several manufacturers for this purpose (Phaminogen, San Diego; R & D Systems, N4N). The highest producing cell clones were tested for the stable expression of p40. One such clone was transfected with pdHL7-14.18-p35 plasmid DNA, as described above, and clones were selected in methotrexate-containing medium. Expression of the desired antibody-IL-12 fusion protein was assayed using an ELISA based on antibody Fc detection. The capture antibody reacted with human H and L chains, and the detection utilized an antibody specific for human Fc. Positive clones were expanded in selection medium and the product was purified by binding to and elution from protein A Sepharose as described above. Eluted proteins were analyzed by PAGE and detected by staining with Coomassie Blue.
4.3 Activities of Antibody-IL-12 Fusion Proteins
As summarized in Table 1, fusion protein-expressing cell clones were obtained by either simultaneous transfection and sequential transfection but more highly productive clones were obtained using sequential transfection. The product secreted by two individual transfectants were analyzed for chain composition. The SDS-PAGE analysis is shown in
The biological activities of the whole antibody-IL-12 fusion proteins are shown in
Comparison of Co-transfection and Sequential
Transfection of IL-12 Fusion Protein Expression
Frequency of Positive
Expression Level (ng/ml)
20, 22, 244, 386
18, 19, 19, 45, 48, 60, 67, 93,
97, 128, 177, 244, 256, 345,
348, 366, 371, 386, 504, 554,
731, 757, 821, 2000
The methods just described for the production of dimeric antibody and Fc-based fusion proteins can also be used in its simpler form to express single chain fusion proteins with IL-12 (those not forming dimers). In this case, a single polypeptide encoding sequence is joined to the sequence for the p35 subunit and co-expressed in the same cell as the free p40 subunit. Either of the two methods, simultaneous or sequential transfection, can be used to produce single-chain heterodimeric fusion proteins. The purpose of such fusion proteins can be either to target IL-12 to an antigen bearing cell, through the fusion of a single-chain Fv (sc-Fv) antibody (Huston and Opperrnann, WO 88/09344) or to combine the very specific immunostimulatory effect of IL-12 together with a protein antigen as an adjuvant. The linking of stimulatory protein and antigen ensures their co-localization following injection into an animal. The antigen can be any polypeptide. These can induce antibodies in animals capable of reacting with tumor, viral or other antigens that have therapeutic value. For example, sc-Fv can be used as it is often advantageous to induce immune responses to antibody V regions including the idiotype (specific antigen binding region) for the purpose of stimulating idiotype networks.
The type of antigen used for such fusion proteins can also be one that normally induces an allergic response, such as the Der p I and Der p II from dust mites, or tropomyosin from several types of shellfish, which can be fused at the DNA level to the p35 subunit of IL-12 and expressed in the same cell with the p40 subunit. Immunization with such fusion proteins would induce strong Th1 helper cell responses that would be useful in desensitizing the disease-causing Th2 response in atopic patients with allergy.
To demonstrate the expression of a single chain fusion protein, a scFv version of the KS-1/4 antibody was constructed. The 5′ end of the protein-encoding portion of fusion gene (an XbaI to AfIII fragment) consists of a leader sequence derived from a mouse k light chain, fused to the mature protein sequence of the KS-1/4 L chain V region. The end of the V region is fused, in frame, to a DNA encoding the simple linker sequence, (Gly4Ser)3, described by others (Huston and Oppermann, WO 88/09344) followed, in frame, by the sequence encoding the H chain V region of KS-1/4. The 3′ end of this scFv contains a XmaI site, compatible with ligation to the 5′ end of the human and mouse versions (XmaI to XhoI fragments) of the p35 subunit of IL-12. The final XbaI to XhoI fragments were inserted into the corresponding sites of the same expression vector (pdC) used to express the free IL-12 subunits to give vectors pdC-SCA-hu-p35 and pdC-SCA-mu-p35.
These vectors were introduced into a human p40 expressing cell line and grown in medium containing methotrexate (0.1 μM). Fusion protein-expressing, drug-resistant clones were identified by ELISA assays specific for the species of p35 utilized in the construct (i.e., an IL-12 human p40 antibody was used for antigen capture, and specific anti-mouse or human-p35 antibodies were used for detection). Culture media from each type of single-chain fusion protein were used to determine their amounts so that relative specific activities could be calculated. Serial dilutions of each sample were tested for the ability to induce IFN-γ secretion as detailed above in Example 2. The results are shown in
The activity results with both whole antibody and single chain IL-12 fusion proteins suggest that the amino terminus of the p35 chain may be important to receptor binding since fusions appear to reduce activity. Nonetheless, the antibody-IL-12 molecules are still very potent inducers of IFN-γ at concentrations above 1 ng/ml. The concentration of such molecules in treated animals is expected to be several orders of magnitude higher than this both in the circulation, and at the target site of action.
A possible way to increase the specific activity of antibody-IL-12 fusion proteins would be to insert a flexible peptide linker between the antibody and p35 sequences thus giving more freedom to the amino terminal sequences of this subunit. A sequence such as the (GIy4Ser)3 linker, described above, could be used in this manner. One possible problem with this approach is that such a linker could be immunogenic, especially when fused to a powerful immune stimulator such as IL-12.
The antibody-IL-12 fusion proteins were tested for their pharmacokinetic behavior following intravenous injection into Balb/c mice. Blood was collected from mice by retro-orbital bleeding and stored at 4� C. in Eppendorf micro-centrifuge tubes. ELISA methods were used to measure the amount of human antibody, as well as the amount of intact IL-12 fusion protein, remaining in the blood at increasing time points. The first ELISA measuring human antibody utilizes an antibody against human H and L chains for capture and an anti-human Fc antibody for detection. The fusion protein-specific assay uses the same first capture step, but an anti-p40 subunit antibody for detection. As depicted in
The murine colon carcinoma, CT26, is particularly insensitive to treatment with systemic administration with mouse IL-12 at non-toxic doses. Martinotti, et al., Eur. J. Immunol. 25: 137-146 (1995). Some efficacy has been found when systemic IL-12 administration has been combined together with repeated vaccination of irradiated CT26 cells, engineered to secrete IL-2. Vagliani, et al., Cancer Res. 56: 467-470 (1996). An alternative approach to successful therapy involved the engineering CT26 to secrete low levels of IL-12. This was ineffective unless mice were first treated with antibodies to deplete CD4+ cells. Martinotti, et al., Eur. J. Immunol. 25: 137-146 (1995), presumably due to an immunosuppressive effect of these cells after exposure to the engineered tumors in vivo. Still another approach of engineering much higher IL-12 secretors was far more successful, thus indicating that the amount of local IL-12 was critical in establishing an immune response to subcutaneous tumors, Colombo, et al., Cancer Res. 56: 2531-2534 (1996). In this case, however, there was no demonstration of treatment of established, disseminated tumors similar to what would be seen in the clinical setting. The purpose of the present experiment was to evaluate the efficacy of antibody-IL-12 fusion proteins for the treatment of murine colon carcinoma, CT26.
CT26 cells were transfected with a cDNA encoding the antigen recognized by the KS-1/4 antibody, referred to as either KS antigen (KSA) or epithelial cell adhesion molecule (EpCAM). Clones expressing this protein on their surface were identified by immunostaining with KS-1/4 and fluorescence activated cell sorting (FACS) analysis. Cells from one clone, stably expressing KSA (clone 21.6), were injected into the tail vein of Balb/c mice (1�105 per mouse). Untreated mice formed extensive pulmonary metastases by day 28 and died within 40 days of inoculation. This growth rate was virtually the same as the parental cells indicating that the expression of the human KSA had no effect on CT26 immunogenicity or ability to form tumors.
The efficacy of the antibody-IL-12 fusion protein for therapy of CT26 metastases was tested in this mouse model using the hybrid human/mouse form which has activity on mouse cells. Following tumor cell injection, mice received injections of either PBS (no treatment control), the KS-1/4-IL-2 fusion protein (positive control), KS-1/4 antibody with free IL-2 (negative control) or the KS-1/4-IL-12 fusion protein (test sample). Treatment began on day 4, a time when established metastases are readily detectable by histological staining in the lungs of animals, and continued daily for 5 days. On day 28 after tumor cell inoculation, animals were euthanized and their lungs examined for the presence of tumor. The weights of the lungs were also measured to determine the amount of tumor mass, relative to tumor-free mice. The results are summarized in Table 2. Untreated animals had extensive metastatic disease characterized by near complete surface coverage of the organ with tumor via fusion of individual metastatic nodules. The weights of the lungs increased by an average of three-fold, indicating that the tumor masses actually made tip the majority of the organ. Treated animals had little if any evidence of metastases, with some animals completely free of tumor. None of the animals showed any overt sign of toxicity during the treatment process. Thus, unlike treatment with systemic IL-12, antibody-IL-12 fusion protein therapy can eradicate established metastatic CT26 colon carcinoma.
Treatment of Murine Colon Carcinoma Lung Metastases
in SCID Mice with Antibody-IL-12 Fusion Proteins
Metastatic Score
Organ Weights
3, 3, 3, 3, 3, 3
3, 3, 3, 3, 3
Hu-KS-1/4 + IL-2
3, 3, 3, 3, 3
2, 1, 1, 1, 1
1, 1, 1, 1, 1
Experimental lung metastases were induced by intravenous injection of 105 CT26-KSA cells. Treatment began three days later with intravenous injection of 10 μg of the humanized KS-1/4 antibody or the indicated fusion protein for five consecutive days.
Animals were sacrificed and the metastatic score was determined by the extent of surface coverage: 0 = no visible metastatic foci; 1 = less than 5% of the surface covered; 2 = 5 to 50% of the surface covered; and 3 = more than 50% of the lung surface is covered with metastatic foci.
The humanized KS-1/4 antibody IL-12 fusion protein in PBS buffer, made with the murine p35 subunit (HuKS-1/4-mIL-12), was injected into Balb/c mice intravenously (5 μg/day�5). Control mice received the same antibody, in the same amounts, but with no attached IL-12. Neither injection solution contained any other type of adjuvant. On day 10, blood samples were collected into microcentrifuge tubes by retro-orbital bleeding and plasma were prepared by collecting blood samples in plastic tubes containing sodium citrate, followed by centrifugation at full speed in an Eppendorf tabletop microcentrifuge. ELISA plates (96-well) were coated with the HuKS-1/4 protein containing human constant region and used to capture any mouse antibodies made in response to the immunization. After washing away unbound material, the bound mouse antibodies were detected with goat anti-mouse Fc antibody (Jackson ImmunoResearch) coupled to horse-radish peroxidase. Any bound antibodies could be directed to either the human constant regions or the variable region, both of which are shared between the HU-KS-1/4 and the fusion proteins.
As depicted in
The immunogenicity of IL-12 fusion proteins administered by various routes is tested by injecting a solution of the fusion protein (such as that described above) in PBS or other biocompatible buffer, or a known adjuvant such as Freund's incomplete or complete adjuvant. For example, single or multiple subcutaneous, intradermal or intraperitoneal injections can be given every two weeks. Alternatively, the fusion protein can be administered first by subcutaneous injection and then followed by intraperitoneal injection. Freund's adjuvant cannot be used for human use, due to the irritation at the injection site. Alternative adjuvants such as precipitates of aluminum hydroxide (Alum) are approved for human use and can be used in the present invention. New organic chemical adjuvants based on squalenes and lipids can also be used for injections into the skin.
The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.
|Cited Patent
|Filing date
|Publication date
|Aug 11, 1978
|Apr 1, 1980
|The Wistar Institute
|Method of producing antibodies
|Sep 23, 1982
|Sep 4, 1984
|Miles Laboratories, Inc.
|Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
|Sep 23, 1985
|Jun 30, 1987
|The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
|Target specific cross-linked heteroantibodies
|Nov 30, 1984
|Oct 27, 1987
|Kiren-Amgen, Inc.
|DNA sequences encoding erythropoietin
|Apr 8, 1983
|Mar 28, 1989
|Genentech, Inc.
|Recombinant immunoglobin preparations
|Jan 19, 1989
|Aug 7, 1990
|Genex Corporation
|Single polypeptide chain binding molecules
|Apr 21, 1988
|Dec 4, 1990
|Eli Lilly And Company
|Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
|Feb 23, 1989
|May 28, 1991
|Cancer Biologics, Inc.
|Detection of necrotic malignant tissue and associated therapy
|Aug 14, 1990
|Dec 17, 1991
|Immunex Corporation
|Fusion proteins comprising GM-CSF and IL-3
|Mar 2, 1990
|Jan 21, 1992
|Genentech, Inc.
|Gamma interferon-interleukin-2 synergism
|Jan 2, 1991
|Feb 25, 1992
|Creative Biomolecules, Inc.
|Biosynthetic antibody binding sites
|Jul 13, 1989
|May 19, 1992
|G. D. Searle & Co.
|Covalently linked polypeptide cell modulators such as interferon-lymphotoxin conjugates
|Nov 22, 1989
|May 26, 1992
|Genentech, Inc.
|Hybrid immunoglobulins
|Sep 26, 1991
|Apr 6, 1993
|Immunex Corporation
|Method for improving autologous transplantation
|Dec 16, 1991
|Jul 6, 1993
|Genentech, Inc.
|Lymphocyte homing receptor/immunoglobulin fusion proteins
|Oct 25, 1991
|Jul 6, 1993
|Medical Research Council
|Recombinant altered antibodies and methods of making altered antibodies
|May 19, 1988
|Nov 2, 1993
|Creative Biomolecules, Inc.
|Polypeptide linkers for production of biosynthetic proteins
|Jan 22, 1990
|May 24, 1994
|Therapeutic interleukin-2-antibody based fusion proteins
|Jun 10, 1993
|Sep 20, 1994
|Protein Design Labs, Inc.
|Chimeric ligand/immunoglobulin molecules and their uses
|Oct 19, 1992
|Oct 25, 1994
|Hoechst Aktiengesellschaft
|Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|Mar 30, 1994
|Mar 21, 1995
|The United States Of America As Represented By The Department Of Health And Human Services
|Gene therapy
|Dec 8, 1992
|Jun 27, 1995
|Genentech, Inc.
|Hybrid immunoglobulins
|Oct 23, 1987
|Aug 15, 1995
|Kirin-Amgen, Inc.
|Production of recombinant erythropoietin
|Sep 18, 1990
|Oct 10, 1995
|Genetics Institute, Inc.
|Natural killer stimulatory factor
|Apr 12, 1994
|Jan 2, 1996
|Immunex Corporation
|CD30 ligand
|Jan 21, 1994
|May 7, 1996
|Genentech, Inc.
|Recombinant DNA encoding hybrid immunoglobulins
|Oct 18, 1994
|Jul 23, 1996
|Sloan-Kettering Institute For Cancer Research
|Prostate-specific membrane antigen
|Sep 14, 1994
|Jul 30, 1996
|Fuji Immunopharmaceuticals Corporation
|Expression and export technology of proteins as immunofusins
|May 6, 1993
|Aug 6, 1996
|Merck Frosst Canada, Inc.
|Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
|Jun 7, 1995
|Aug 20, 1996
|Kirin-Amgen, Inc.
|Production of erythropoietin
|Feb 6, 1995
|Sep 3, 1996
|Eli Lilly And Company
|Anti-obesity proteins
|Jun 7, 1995
|Dec 17, 1996
|Protein Design Labs, Inc.
|Humanized immunoglobulins
|Sep 14, 1994
|Feb 11, 1997
|The General Hospital Corporation
|Bispecific antibodies for selective immune regulation and for selective immune cell binding
|Mar 27, 1995
|Mar 11, 1997
|Immunomedics, Inc.
|Radiolabelled antibody cytotoxic therapy of infectious or autoimmune disease
|Feb 2, 1995
|Mar 25, 1997
|New England Deaconess Hospital
|Recombinant human erythropoietin mutants and therapeutic methods employing them
|Jun 6, 1995
|Apr 8, 1997
|Kirin-Amgen, Inc.
|Production of erythropoietin
|Jun 7, 1995
|Apr 29, 1997
|Scotgen Biopharmaceuticals Incorporated
|Antibodies with altered effector functions
|Apr 26, 1994
|Jun 17, 1997
|Children's Hospital Medical Center Corp.
|Angiostatin protein
|May 23, 1994
|Jul 8, 1997
|Therapeutic antibody based fusion proteins
|Jul 27, 1994
|Jul 22, 1997
|Gillies; Stephen D.
|Recombinant antibody cytokine fusion proteins
|Apr 18, 1995
|Jul 22, 1997
|Hoffmann-La Roche Inc.
|P-40 homodimer of interleukin-12
|Jun 1, 1995
|Sep 16, 1997
|Chiron Corporation
|Treatment for biological damage using tumor necrosis factor and a free-radical scavenger
|Oct 5, 1994
|Oct 21, 1997
|Genencor International, Inc.
|DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
|Oct 6, 1993
|Nov 18, 1997
|University Of Washington
|Human erythropoietin gene; high level expression in stably transfected mammalian cells
|Feb 6, 1995
|Nov 25, 1997
|Eli Lilly And Company
|Anti-obesity proteins
|Jan 24, 1991
|Jan 20, 1998
|Bristol-Myers Squibb Company
|Mixed specificity fusion proteins
|Jun 30, 1995
|Jan 27, 1998
|Centro De Immunologia Molecular
|Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
|Mar 17, 1995
|Feb 17, 1998
|Eli Lilly And Company
|Anti-obesity proteins
|Sep 25, 1996
|Mar 3, 1998
|Tanox Biosystems, Inc.
|Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|Sep 14, 1995
|Mar 10, 1998
|Fuji Immunopharmaceuticals Corp.
|Expression and export technology of proteins as immunofusins
|Feb 13, 1996
|Mar 17, 1998
|Takeda Chemical Industries, Ltd.
|DNA encoding a fusion protein comprising a viral antigen and lymphokine
|May 26, 1995
|Mar 31, 1998
|The Children's Medical Center Corporation
|Method of inhibiting angiogenesis
|Jun 6, 1995
|May 26, 1998
|Amgen Inc.
|Production of erythropoietin
|Jun 28, 1996
|May 26, 1998
|Eli Lilly And Company
|Methods for treating diabetes
|Apr 28, 1994
|Jun 2, 1998
|United Biomedical, Inc.
|Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
|May 23, 1995
|Jun 23, 1998
|Genentech, Inc.
|Monoclonal antibodies directed to the her2 receptor
|Oct 17, 1996
|Sep 1, 1998
|Chiron Corporation
|Human IL-2 as a vaccine adjuvant
|Jun 27, 1994
|Sep 15, 1998
|The Board Of Trustees Of The Leland Stanford Junior University
|Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|Jun 7, 1995
|Oct 27, 1998
|President And Fellows Of Harvard College
|Immunomodulatory peptides
|May 19, 1994
|Oct 27, 1998
|The Regents Of The University Of California
|Methods and composition for in vivo gene therapy
|Mar 8, 1996
|Nov 17, 1998
|The Children's Medical Center Corporation
|Angiostatin fragments and method of use
|Nov 4, 1992
|Nov 17, 1998
|City Of Hope
|Antibody construct
|Dec 18, 1997
|Dec 1, 1998
|Immunex Corporation
|Methods of stimulating hematopoietic cells with flt3-ligand
|Oct 22, 1996
|Dec 29, 1998
|The Children's Medical Center Corporation
|Therapeutic antiangiogenic compositions and methods
|Nov 3, 1994
|Jan 5, 1999
|Amgen Inc.
|Erythropoietin isoforms
|Jun 6, 1995
|Jan 12, 1999
|G. D. Searle & Co.
|Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors
|Apr 26, 1995
|Mar 23, 1999
|The Children's Medical Center Corporation
|Methods of expressing angiostatic protein
|May 28, 1997
|Mar 23, 1999
|Syntex (U.S.A.) Inc.
|3-aroylbenzylpyridazinone derivatives
|Apr 29, 1994
|Mar 30, 1999
|Abbott Laboratories
|DNA encoding human a erythropoietin analog
|Aug 17, 1994
|Mar 30, 1999
|The United States Of America As Represented By The Department Of Health And Human Services
|Method of producing single-chain Fv molecules
|Feb 8, 1995
|Apr 6, 1999
|Whitehead Institute For Biomedical Research
|Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
|Dec 19, 1997
|Jun 1, 1999
|Tanox, Inc.
|Hybrid with interferon-β and an immunoglobulin Fc joined by a peptide linker
|Jun 5, 1996
|Jul 13, 1999
|Powderject Vaccines, Inc.
|IL-12 gene therapy of tumors
|Aug 2, 1993
|Sep 21, 1999
|Kirin-Amgen, Inc.
|Production of erthropoietin
|Nov 8, 1996
|Nov 30, 1999
|Royal Free Hospital School Of Medicine
|Interleukin-12 fusion protein
|Jun 17, 1994
|Nov 30, 1999
|The Rockefeller University
|Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
|Dec 28, 1995
|Jun 27, 2000
|Dendreon Corporation
|Immunostimulatory method
|Jan 17, 1995
|Jul 11, 2000
|The Brigham And Women's Hospital, Inc.
|Receptor specific transepithelial transport of immunogens
|Feb 28, 1997
|Aug 8, 2000
|Genetics Institute, Inc.
|Chimeric polypeptides containing chemokine domains
|Mar 5, 1996
|Jan 2, 2001
|Genentech, Inc.
|Mer receptor activation by gas6
|Apr 9, 1998
|Jan 9, 2001
|G. D. Searle & Company
|Anti-αvβ3 integrin antibody antagonists
|May 21, 1999
|May 15, 2001
|M. Rigdon Lentz
|Method and compositions for treatments of cancers
|Mar 3, 1997
|Aug 21, 2001
|Board Of Regents, The University Of Texas System
|Immunoglobulin-like domains with increased half-lives
|Apr 20, 1999
|Sep 4, 2001
|The Regents Of The University Of California
|Modified immunoglobin molecules and methods for use thereof
|Aug 21, 1992
|Sep 18, 2001
|Scripps Research Institute
|Method for tapping the immunological repertoire
|Oct 16, 1998
|Jan 1, 2002
|Pharmacopeia, Inc.
|Incorporation of phosphorylation sites
|Jun 28, 2000
|Jan 22, 2002
|Roche Diagnostics Gmbh
|Erythropoietin conjugates
|May 11, 1999
|Feb 19, 2002
|Bayer Corporation
|Interleukin-2 mutein expressed from mammalian cells
|Mar 3, 1999
|Jun 18, 2002
|Frank W. Falkenberg
|Compositions and methods for treatment of tumors and metastatic diseases
|Nov 13, 1998
|Aug 6, 2002
|University Of Iowa Research Foundation
|Immunostimulatory nucleic acid molecules for activating dendritic cells
|Jan 8, 1999
|Sep 3, 2002
|Repligen Corporation
|CTLA4-Cγ4 fusion proteins
|Jul 25, 1997
|Nov 5, 2002
|Dade Behring Marburg Gmbh
|Method for detecting and determining mediators
|Jul 24, 1998
|Nov 26, 2002
|The Brigham And Women's Hospital, Inc.
|Receptor specific transepithelial transport of therapeutics
|May 5, 2000
|Dec 31, 2002
|Wake Forest University School Of Medicine
|Compositions and methods for identifying antigens which elicit an immune response
|Aug 1, 2000
|Jan 14, 2003
|American Bioscience, Inc.
|Methods and formulations of cremophor-free taxanes
|Sep 3, 1997
|Apr 22, 2003
|Gsf Forschungszentrum Fur Umwelt Und Gesundheit Gmbh
|Bi-and trispecific antibodies for the induction of anti-tumor immunity
|Jun 27, 2000
|Jun 24, 2003
|Hoffmann-La Roche Inc.
|Erythropoietin conjugates
|Apr 7, 2000
|Jul 1, 2003
|Amgen, Inc.
|Chemically modified novel erythropoietin stimulating protein compositions and methods
|Aug 9, 2000
|Sep 9, 2003
|Emd Lexigen Research Center Corp.
|Multiple cytokine protein complexes
|Dec 27, 1996
|Sep 16, 2003
|Genentech, Inc.
|OB protein-polymer chimeras
|Aug 11, 1998
|Sep 30, 2003
|The Regents Of The University Of California
|Methods and compositions for in vivo gene therapy
|Sep 17, 1999
|Nov 11, 2003
|The Trustees Of The University Of Pennsylvania
|Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
|May 31, 1994
|Jun 15, 2004
|Research Development Foundation
|Antibody delivery system for biological response modifiers
|Dec 4, 2001
|Jan 4, 2005
|Emd Lexigen Research Center Corp.
|Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|Mar 5, 2004
|Nov 28, 2006
|Heraeus Electro-Nite International N.V.
|Measurement device for determining oxygen activity in molten metal or slag
|Jun 24, 2003
|Nov 28, 2006
|Emd Lexigen Research Center Corp.
|Multiple cytokine protein complexes
|Sep 7, 2004
|Jun 5, 2007
|Emd Lexigen Research Center Corp.
|Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|May 21, 2007
|Aug 18, 2009
|Merck Patent Gmbh
|Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|Nov 20, 2006
|Sep 1, 2009
|Merck Patent Gmbh
|Methods of targeting multiple cytokines
|Apr 6, 1999
|Dec 20, 2001
|The General Hospital Corporation
|Fusion proteins with immunoglobulin portions, the preparation and use thereof
|Oct 23, 1991
|Mar 28, 2002
|Kin-Ming Lo
|E.coli produced immunoglobulin constructs
|Oct 11, 2001
|Jun 27, 2002
|Kin-Ming Lo
|Expression and export of interferon-alpha proteins as Fc fusion proteins
|Aug 17, 1999
|Oct 3, 2002
|Michael Gallo
|Generation of modified molecules with increased serum half-lives
|May 14, 2001
|Oct 10, 2002
|Gillies Stephen D.
|Cytokine immunoconjugates
|Feb 9, 2001
|Oct 10, 2002
|Gillies Stephen D.
|Enhancing the circulating half-life of antibody-based fusion proteins
|Aug 8, 2002
|Dec 19, 2002
|Blumberg Richard S.
|Receptor specific transepithelial transport of therapeutics
|Dec 4, 2001
|Dec 19, 2002
|Gillies Stephen D.
|Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|Jul 19, 2002
|Jan 2, 2003
|Neose Technologies, Inc.
|Vitro modification of glycosylation patterns of recombinant glycopeptides
|Aug 8, 2002
|Jan 16, 2003
|Blumberg Richard S.
|Receptor specific transepithelial transport of therapeutics
|Mar 7, 2002
|Mar 6, 2003
|Lexigen Pharmaceuticals Corp.
|Expression technology for proteins containing a hybrid isotype antibody moiety
|Jun 29, 2001
|Mar 13, 2003
|Gillies Stephen D.
|Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|Feb 24, 1999
|Jun 5, 2003
|Stephen Gillies
|Enhancing the circulating half life of antibody-based fusion proteins
|Nov 12, 2002
|Jul 24, 2003
|Kin-Ming Lo
|Expression and export of angiogenesis inhibitors as immunofusins
|Jun 26, 2002
|Jul 24, 2003
|Gillies Stephen D.
|Cytokine immunoconjugates
|May 3, 2002
|Aug 21, 2003
|Lexigen Pharmaceuticals Corp.
|Recombinant tumor specific antibody and use thereof
|Dec 4, 2002
|Sep 4, 2003
|Emd Lexigen Research Center Corp.
|Immunocytokines with modulated selectivity
|Mar 29, 2002
|Sep 4, 2003
|Lexigen Pharmaceuticals Corp.
|Reducing the immunogenicity of fusion proteins
|Feb 22, 2001
|Jan 22, 2004
|Luciano Zardi
|Compositions and methods for treatment of angiogenesis in pathological lesions
|May 21, 2003
|Feb 19, 2004
|Emd Lexigen Research Center Corp.
|Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
|Dec 27, 2001
|Mar 4, 2004
|Silke Schumacher
|Bifunctional fusion proteins with glucocerebrosidase activity
|Apr 18, 2003
|Mar 18, 2004
|Lexigen Pharmaceuticals Corp.
|Expression and export of anti-obesity proteins as Fc fusion proteins
|Jun 24, 2003
|Apr 15, 2004
|Gillies Stephen D.
|Multiple cytokine protein complexes
|Feb 18, 2002
|Apr 29, 2004
|Stephen Gillies
|Artificial proteins with reduced immunogenicity
|Nov 14, 2003
|Sep 16, 2004
|Emd Lexigen Research Center Corp.
|IL-15 immunoconjugates and uses thereof
|Feb 18, 2002
|Sep 16, 2004
|Carr Francis J.
|Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
|Dec 16, 2003
|Oct 14, 2004
|Emd Lexigen Research Center Corp.
|Immunocytokine sequences and uses thereof
|Aug 27, 2004
|Mar 31, 2005
|Emd Lexigen Research Center Corp.
|Enhancing the circulating half-life of interleukin-2 proteins
|Title not available
|Apr 16, 1987
|Nov 3, 1988
|Hoechst Ag
|Bifunktionelle proteine
|Mar 23, 1985
|Oct 16, 1985
|Takeda Chemical Industries, Ltd.
|DNA and use thereof
|Aug 7, 1986
|Apr 8, 1992
|THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce
|Adoptive immunotherapy as a treatment modality in humans
|Mar 10, 1987
|Mar 9, 1988
|Toray Industries, Inc.
|Interferon conjugate and production thereof using recombinant gene
|Jul 30, 1987
|Feb 24, 1988
|Cetus Oncology Corporation
|Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2
|Jun 1, 1988
|May 10, 1995
|Dana-Farber Cancer Institute, Inc.
|Bifunctional antibody constructs and method for selectively destroying cell populations
|Sep 22, 1988
|Jul 6, 1994
|Bristol-Myers Squibb Company
|Antibody heteroconjugates for the killing of HIV-infected cells
|Oct 3, 1988
|Mar 23, 2005
|Genentech Inc.
|Adheson variants, nucleic acid encoding them and compositions comprising them
|May 19, 1988
|Apr 5, 1995
|Creative Biomolecules, Inc.
|Targeted multifunctional proteins
|Dec 2, 1988
|May 16, 1990
|The Du Pont Merck Pharmaceutical Company
|Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
|Jan 25, 1989
|Apr 15, 1998
|Yeda Research And Development Company Limited
|Human IFN-beta2/IL-6, its purification and uses
|May 25, 1989
|Jan 19, 1994
|Istituto Nazionale Per La Ricerca Sul Cancro
|Monoclonal antibody specific to a fibronectin sequence expressed in transformed cells, hybridoma secreting said antibody and use of said monoclonal antibody in the diagnosis of tumors
|Jul 3, 1989
|Sep 15, 1993
|RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation)
|Immunoconjugates for cancer diagnosis and therapy
|Dec 22, 1989
|Apr 26, 1995
|Oncogen Limited Partnership
|Novel monoclonal antibody to human carcinomas
|May 1, 1990
|Dec 22, 1993
|Research Development Foundation
|A novel antibody delivery system for biological response modifiers
|Aug 2, 1989
|Apr 17, 1996
|University Of Maryland
|Novel infectious bursal disease virus
|Dec 9, 1990
|Mar 4, 1998
|F. Hoffmann-La Roche Ag
|Cytotoxic lymphocyte maturation factor
|Jan 21, 1991
|Dec 15, 2004
|Bristol-Myers Squibb Company
|Recombinant immunoconjugates for therapy comprising interleukin 2
|Apr 7, 1992
|Nov 4, 1992
|Rohm And Haas Company
|Hybrid polypeptide containing an avidin binding polypeptide
|May 12, 1992
|Feb 23, 2005
|Merck & Co., Inc.
|A method for reducing the immunogenicity of antibody variable domains
|Aug 24, 1992
|Nov 25, 1998
|Fred Hutchinson Cancer Research Center
|Hybrid cytokines
|Aug 16, 1994
|Mar 23, 2005
|Kirin-Amgen, Inc.
|Erythropoietin analogs with additional glycosylation sites
|Apr 19, 1990
|Aug 23, 1995
|Genetics Institute, Inc.
|Cysteine added variants of EPO and chemical modifications thereof
|Jun 27, 1995
|Apr 28, 2004
|Centro de Inmunologia Molecular
|Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
|Sep 6, 1995
|Nov 14, 2001
|MERCK PATENT GmbH
|Immunoconjugates II
|Dec 9, 1990
|Jul 25, 2007
|F. Hoffmann-La Roche Ag
|Cytotoxic lymphocyte maturation factor 40kD subunit and monoclonal antibodies directed thereto
|May 13, 1999
|Mar 16, 2005
|Merck Patent Gmbh
|Fused protein
|Title not available
|Title not available
|Title not available
|Title not available
|Title not available
|Abaza et al., (1992) "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization" Journal of Protein Chemistry, vol. 11, No. 5: pp. 433-444.
|Abstract XP-002116766, (1996) "Prostaglandins, their inhibitors and cancer" Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 54, No. 2, pp. 83-94.
|Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," Science, 263:235-237.
|Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," Molecular Immunology, 30(1):105-108.
|Arenberg et al. (1996) "Interferon-gamma-inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. Exp. Med,. vol. 184, pp. 981-992.
|Arenberg et al. (1996) "Interferon-γ-inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. Exp. Med,. vol. 184, pp. 981-992.
|Bacha et al., (1988). "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein", J. Experimental Medicine, vol. 167, pp. 612-622.
|Bachelot et al., (Mar. 1998) "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo", Proceedings of the Annual Meeting of the American Association for Cancer Research, vol. 39, pp. 271, Abstract # 1856.
|Barnett et al. (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," Biochimica et Biophysica Acta, 1209:130-139.
|Baselga, et al (1998) "Recombinant Humanized Anti-HER2 Antibody (Herceptin.TM.) Enhances the Antitumor activity of Paclitazel and Doxorubicin against HER3/neu Overexpressing Human Breast Cancer Xenografts." Cancer Research, vol. 58, pp. 2825-2831.
|Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," Clinical Cancer Research, vol. 5, No. 12, pp. 4259-4263.
|Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," Mol. Immunol., 30(4):379-386.
|Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," Proc. Natl. Acad. Sci., 93:7826-7831.
|Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," Proc. Natl. Acad. Sci. USA, vol. 93, pp. 2702-2707.
|Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," J Clin Invest., 98(12):2801-2804.
|Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," J Exp. Med., 183(50):2361-6.
|Beutler et al., (1988) "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator", Ann. Rev. Biochem., vol. 57, pp. 505-518.
|Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," Ann. Rev. Biochem., 57:505-518.
|Bissery et al., (1997), Cancer Therapeutics: Experimental and Clinical Agents, Teicher Edition, Ch. 8.
|Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," Respiratory Drug Delivery, 8:309-312.
|Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins" Cancer Research, vol. 45, pp. 1214-1221.
|Boehm et al. (1997) "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," Letters to Nature, vol. 390, pp. 404-407.
|Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," Biochemical and Biophysical Research Communications, vol. 252, pp. 190-194.
|Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," The Journal of Biological Chemistry, 268(21):15883-15993.
|Boulianne et al., (1984), "Production of Functional Chimaeric Mouse/Human Antibody," Nature, 312:643-6.
|Briggs et al., (1974), "Hepative Clearance of Intact and desialylated Erythropoietin," American Journal of Physiology, 227(6):1385-1388.
|Brooks et al. (1994), "Integrin alphavbeta3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," Cell, vol. 79, pp. 1157-1164.
|Brooks et al. (1994), "Integrin αvβ3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," Cell, vol. 79, pp. 1157-1164.
|Bubenik et al., (1995), "Interleukin-2 Gene Therapy of Residual EL-4 Leukaemia Potentiates the Effect of Cyclophosphamide Pretreatment," J. Cancer Res. Clin. Oncol., 121:39-43.
|Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," Archives of Biochemistry and Biophysics, 307:2:411-415.
|Burgess et al., (1990), "Possible Dissociation of the heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, "Journal of Cell Biology, vol. 111, pp. 2129-2138.
|Canfield et al. (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," Journal of Experimental Medicine, vol. 173, No. 6, pp. 1483-1491.
|Cao et al. (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," The Journal of Biological Chemistry, vol. 272, No. 36, pp. 22924-22928.
|Cao et al., (1996), "Kringle Domains of Human Angiostatin," The Journal of Biological Chemistry, vol. 271, No. 46, pp. 29461-29467.
|Capon et al. (1989), "Designing CD4 immunoadhesins for AIDS therapy," Nature, vol. 337, pp. 525-531.
|Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," The EMBO Journal, 5:7:1577:1587.
|Chan et al., (1991) "Induction of Interferon gamma Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," J. Exp. Med., pp. 869-879.
|Chan et al., (1991) "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," J. Exp. Med., pp. 869-879.
|Chan et al., (1992), "Mechanisms of IFN-γ Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12). Role of Transcription and mRNA Stability in the Synergistic Interaction Between NKSF and IL-2," J. Immunol., 148:92-98.
|Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," Seminars in Surgical Oncology, vol. 5, pp. 385-390.
|Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," Journal of Biological Chemistry, 271:23:13349-13355.
|Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," Cancer Immuno. Immunother., 39:198-204.
|Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," Nature, vol. 335, pp. 370-372.
|Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin" Nature, vol. 339, pp. 394-397.
|Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," Journal of Immunology, vol. 159,No. 1, pp. 351-358.
|Cheon et al. (1994) "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," Proc. Natl. Acad. Sci. USA 91: 989-993.
|Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," Gynecol. Oncol., 49:291-298.
|Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," Cancer Research, 54:1286-1291.
|Cohen, S. L. et al., (Aug. 15, 1996), "Human leptin characterization," Nature, vol. 382, p. 589.
|Cole et al. (1997) "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," Journal of Immunology, vol. 159, pp. 3613-3621.
|Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," Proc. Natl. Acad. Sci, 85:7709-7713.
|Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," Cancer Research, vol. 56, pp. 2531-2534.
|Conner et al., (2004), "Ex vivo Evaluation of Anti-EpCAM Immunocytokine huKS-IL2 in Ovarian Cancer," J. Immunotherapy, 27:211-219.
|Cruse et al., (1995), Illustrated Dictionary of Immunology, CRC Press, NY, p. 156-7.
|D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," Proc. Natl. Acad. Sci. USA, vol. 91, pp. 4082-4085.
|D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," J. Exp. Med., vol. 176, pp. 1387-1398.
|Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," Biochemistry, 41 :14524-14531.
|Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," Cancer Immunol. Immunother., 52:297-308.
|de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in Human IgG Receptors, pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co.
|Desai et al., (1992), "IL-12 Receptor. II. Distribution and Regulation of Receptor Expression," J. Immunol., 148:3125-32.
|Ding et al., (Sep. 1988), "Zinc-Dependent Dimers Observed in Crystals of Human Edostatin," Proceedings of the National Academy of Sciences of USA, vol. 95, No. 18, pp. 10443-10448.
|Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," Clin Cancer Res., 4(10):2551-7.
|Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," Hybridoma, 10(2):211-217.
|Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," Molecular Immunology, 29(12):1487-1491.
|Duncan et al., (1988), "The Binding Site for C1q on IgG," Nature, 332:738-740.
|Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," J. Cell. Biochem. Supp, vol. 161, pp. 156-166.
|Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," Nephrol. Dial. Transplant., 16:3-13.
|Eisenthal, (1990) "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," Cancer Immunol. Immunotherap. vol. 31, pp. 342-348.
|Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," Blood, 87(7):2702-2713.
|Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," Blood, 89(2):493-502.
|Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," The J. of Immunology, vol. 146, pp. 2446-2452.
|Fell et al., (1992), "Chimeric L6 antitumor antibody," The J. of Biol. Chem., 267:22:15552-15558.
|Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," Blood, 85(5):1229-1236.
|Friedman, J. M. et al., (Oct. 22, 1998). "Leptin and the regulation of body weight in mammals," Nature, vol. 395, pp. 763-770.
|Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neutroblastoma," Cancer, 80:317-33.
|Gan et al., (1999), "Specific enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," Clin. Diagn. Lab. Immunol., 6(2):236-42.
|Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action in Neutrophils", Science, vol. 226, pp. 1339-1134.
|Gately et al., (1998), "The Interleuking-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses" Annu. Rev. Immunol., vol. 16, pp. 495-521.
|Gillessen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist" Eur. J. Immunol., vol. 25, pp. 200-206.
|Gillies et al. (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," Hum. Antibod. Hybridomas vol. 1, No. 1, pp. 47-54.
|Gillies et al., (1989), "Expression of Human Anti-Tetanus toxoid antibody in Transfected Murine Myeloma Cells," Bio/Technology, vol. 7, pp. 799-804.
|Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," J. Immunol. Methods, vol. 125, pp. 191-202.
|Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," Hybridoma., 10(3):347-56.
|Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," J. Immunology, 146(3):1067-1071.
|Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," Proc. Natl. Acad. Science, vol. 89, pp. 1428-1432.
|Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," Bioconjugate Chem., vol. 4, pp. 230-235.
|Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," Cancer Immunol. Immunother., 51(8):449-60.
|Gillies et al., (2002), "Improved Circulating Half-life and Efficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," Clin. Cancer Res., 8(1):210-6.
|Gillies, et al., (Jun. 1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostrate and colon carcinoma metastases," Journal Immunology, vol. 160, No. 12, pp. 6195-6203.
|Gillies, et al., (May 1999), "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors," Cancer Research, vol. 59, No. 9, pp. 2159-2166.
|Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity," Journal of Immunology, vol. 120, No. 6, pp. 2027-2032.
|Goeddel et al., (1986), "Tumor Necrosis Factors; Gene Structure and Biological Activities," Pharm. Sciences, pp. 597-609.
|Greene et al., (1975), Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells, Proc. Natl. Acad. Sci. USA, 72(12):4923-4927.
|Gren et al., (1983), "A New Type of Leukocytic Interferon,".. Dokl. Biochem., vol. 269, pp. 91-95.
|Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," Cancer Research, 59:3776-3782.
|Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," Blood, vol. 73, No. 8, pp. 2081-2805.
|Gurewich et al., (1988), "Characterization of the Intrinsic Fibrinolytic Properties of Pro-Urokinase Through a Study of Plasmin-Resistant Mutant Forms Produced by Site-Specific Mutagenesis of Lysine," J. Clin. Invest., 82:1956-1962.
|Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," Cancer Immunol. Immunother. vol. 45, pp. 146-148.
|Hammerling et al. (1996), "In Vitro Bioassay for Human Erythropoietin based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," Journal of Pharmaceutical and Biomedical Analysis,14:1455-1469.
|Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," European J. Cancer, 31A(2):261-267.
|Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.8-IL2)," Clin Cancer Res., 2(12):1951-9.
|Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," Methods Mol. Med., 85:123-31.
|Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α-2,8-sialytrasnferase Cdna using anti-GD2 Monoclonal Antibody," Proc. Natl. Acad. Sci. USA., 91 (22):10455-9.
|Harris et al., "Therapeutic Antibodies-the Coming of Age" Tibtech, 11:42-44 (Feb. 1993).
|Harris et al., "Therapeutic Antibodies—the Coming of Age" Tibtech, 11:42-44 (Feb. 1993).
|Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," J. Chromatogr. A., 705:129-134.
|Harvill et al. (Oct. 1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation." Journal of Immunology, vol. 157, No. 7, pp. 3165-3170.
|Harvill et al., (1995), "A IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," Immunotech., 1:95-105.
|Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," Vaccine, vol. 11, Issue 6, pp. 629-636.
|He et al. (1998) "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," J. Immunol. 1029-1035.
|Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcYRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," J. Clin. Invest., 97:2:331-338.
|Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers In Vivo Biology of IL-12 p40 Homodimer," Journal of Immunology, vol. 158, pp. 4381-4388.
|Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," Proc. Natl. Acad. Sci. USA, vol. 83, No. 18, pp. 7059-7063.
|Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," Ann. Rev. Immunol., vol. 3, pp. 31-58.
|Herrmann et al., (1989), "Hematopoeitic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," Journal of Clinical Oncology, vol. 7, No. 2, pp. 159-167.
|Hezareh et al, (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," J. Virol., 75(24):12161-8.
|Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at ⅕ Å Resolution," EMBO Journal, vol. 17, No. 6, pp. 1656-1664.
|Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1/5 � Resolution," EMBO Journal, vol. 17, No. 6, pp. 1656-1664.
|Holden, et al. (2001) "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents" Clinical Cancer Research; vol. 7, No. 9, pp. 2862-2869.
|Holden, et al. (2001) "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents." Proceedings of the American Association for Cancer Research, vol. 42, p. 683.
|Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," Molecular Immunology, vol. 28, No. 9, pp. 1027-1037.
|Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," Biochim. and Biophys. Acta, vol. 1096, No. 4, pp. 345-354(Abstract).
|Hornick et al., (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," Clin. Cancer Res., 5:51-60.
|Hu et al., (1996), "A chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," Cancer Research, 56:4998-5004.
|Huck et al. (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," Nucleic Acids Research, vol. 14, No. 4, pp. 1779-1789.
|Hurn et al., (1980), "Production of Reagent Antibodies," Methods in Enzymology, 70: 104-142.
|Huse et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science, vol. 246, pp. 1275-1281.
|Huston et al., (1988), "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli," Proc. Natl. Acad. Sci. USA, 85:5879-5883.
|Idusogie et al., (2000), "Mapping of the C1q Binding Site of Rituxan, a Chimeric Antibody with a Human IgG1 Fc," J. Immunol., 164(8):4178-4184.
|Imboden et al., (2001), "The Level of MHC Class I Expression of Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," Cancer Res., 61(4):1500-7.
|International Search Report for International Patent Application Serial No. PCT/US98/25978, dated Jun. 18, 1999.
|Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," J. Immunology, 114(6):1726-1729.
|Jones et al., (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, vol. 321, No. 6069, pp. 522-525.
|Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," Journal of Biological Chemistry, 262:12:5723-5731.
|Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4479-4483.
|Junghans et al. (1996) "The protection receptor of IgG catabolism is the B2-micorgobulin-containing neonatal intestinal transport receptor," Proc. Natl. Acad. Sci. USA, vol. 93, No. 11, pp. 5512-5516.
|Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," Proc. Natl. Acad. Sci. USA, vol. 88, pp. 11120-11123.
|Kappel, et al. (1992) "Regulating gene expression in transgenic animals," Current Opinion in Biotechnology 3:548-553.
|Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc.lamda. Receptor Antibodies," Journal of Experimental Medicine, vol. 160, No. 6, pp. 1686-1701.
|Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," The Journal of Pharmacology and Experimental Therapeutics, 283:520-527.
|Kato et al., (1998), "Pharmacokinetics of Erythopoietin in Genetically Anemic Mice," Drug Metabolism and Disposition, 26:126-131.
|Kendra et al., (1999), "Pharmacokinetics and stability of the ch 14.18-interleukin-2 fusion protein in mice," Cancer Immunol. Immunotherapy, vol. 48, pp. 219-229.
|Kim, et al. (1999) "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV" Journal of Interferon and Cytokine Research, vol. 19, pp. 77-84.
|Kim, et al., (May 1997), "An Ovalbumin-IL-12 fusion protein is more effective than oval bumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production." JournalImmunology, vol. 158, No. 9, pp. 4137-4144.
|Kitamura et al. (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," Journal of Cellular Physiology, 140:323-334.
|Ko et al., (2004), "Safety, Pharmcokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)," J. Immunotherapy, 27:232-239.
|Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes", Proc. Natl. Acad. Sci. USA, vol. 81, 7922-7926.
|Kuo, et al. (2001) "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NCl/Endostatin Domain," Journal of Cell Biology, vol. 152, No. 6, pp. 1233-1246.
|Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal-macrophage-colony-stimulating Factor for Neuroblastoma," J. Clin. Oncol., 19:4189-94.
|Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenized with Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7.
|LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," Journal of Biological Chemistry, vol. 268, No. 31, pp. 23311-23317.
|Lazar et al., (1988), "Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," Molecular and Cellular Biology vol. 8, No. 3, pp. 1247-1252.
|Lazar et al., (1988), "Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," Molecular and Cellular Biology vol. 8, No. 3, pp. 1247-1252.
|LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 lmmunoconjugate," Cancer Research, vol. 51, pp. 2694-2698.
|Lieschke, et al., (Jan. 1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo." Nature Biotechnology, vol. 15, No. 1, pp. 35-40.
|Linsley et al. (1991) "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," Journal of Experimental Medicine, vol. 174, No. 3, pp. 561-569.
|Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes", Proc. Natl. Acad. Sci. USA, vol. 82, pp. 8648-8652.
|Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," Science, vol. 239, pp. 395-398.
|Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," Blood, 92:3730-3736.
|lngber et al. (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," Nature, vol. 348, pp. 555-557.
|Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in E. coli.," Hum. Antibod. Hybridomas, 3:123-128.
|Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells" Protein Engineering, vol. 11, No. 6, pp. 495-500.
|Locatelli et al., (2001), "Darbepoetin alfa Amgen," Current Opinion in Investigational Drugs, 2:1097-1104.
|Lode et al., (1997), "Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," J. Natl. Cancer Inst., 89(21):1586-94.
|Lode et al., (1998), "Gene Therapy with a Single Chain Interleukin 12 Fusion Protein Induces T Cell-Dependent Protective Immunity in a Syngeneic Model of Murine Neuroblastoma," Proc. Natl. Acad. Sci. USA, 95:2475-80.
|Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," Pharmcol. Thera., 80:277-292.
|Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," Blood, vol. 91, No. 5, pp. 1706-1715.
|Lode et al., (1999), "Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," Proc. Natl. Acad. Sci. USA, vol. 96, pp. 1591-1596.
|Lode et al., (1999), "Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," Proc. Natl. Acad. Sci. USA, vol. 96, pp. 1591-1596.
|Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," Proc. Natl. Acad. Sci. USA, vol. 96, pp. 8591-8596.
|Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," Immunological Investigations, vol. 29, No. 2, pp. 117-120.
|Lode et al., (2000), "Melanoma Immunotherapy by Targeted II-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD4OL Interaction," J. Clin. Invest., 105(11):1623-30.
|Lode et al., (2000), "What to do with Targeted IL-2," Drugs Today, 36(5):321-36.
|Lotze et al., (1996), "Cytokine Gene Therapy of Cancer Using Interleukin-12: Murine and Clinical Trials," Ann. NY Acad. Sci., 795:440-54.
|Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," Nephrol. Dial. Transplant., 17:66-70.
|MacLean et al., (1996), "Enhancing the Effect of Theratope STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide," J. Immunother., 19(4):309-316.
|Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," Vaccine, 15(15):1687-1698.
|Maghazachi et al., (1997), "Interferon-Inducible Protein-10 and Lymphotactin Induce the Chemotaxis and Mobilization of Intracellular Calcium in Natural Killer Cells through Pertussis Toxin-Sensitive and -Insensitive Heterotrimeric G-Proteins," FASEBJ., 11:765-74.
|Maloney et al., (1994), "Phase 1 Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," Blood, vol. 84, No. 8, pp. 2457-2466.
|Mariani et al., (1997), "Tumor Targeting Potential of the Monoclonal Antibody BC-1 against Oncofetal Fibronectin in Nude Mice Bearing Human Tumor Implants," Cancer, 80:2378-84.
|Mark et al., (Dec. 1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins." Journal of Biological Chemistry, vol. 267, No. 36, pp. 26166-26171.
|Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," Eur. J. Immunol. vol. 25, pp. 137-146.
|McMahan et al., (1991), "A Novel IL-1 Receptor, Cloned From B-Cells by Mammalian Expression is Expressed in Many Cell Types," EMBO J., 10:2821-32.
|Medesan et al. (1997) "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG11," Journal Immunology, vol. 158, No. 5, pp. 2211-2217.
|Mehrotra et al., (1993), "Effects of IL-12 on the Generation of Cytotoxic Activity in Human CD8+ T Lymphocytes," J. Immunol., 151:2444-52.
|Menard et al., (1983), "Generation of Monoclonal Antibodies Reacting with Normal and Cancer Cells of Human Breast," Cancer Res., 43:1295-300.
|Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," Cancer Research, vol. 57, pp. 2890-2895.
|Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcyRII (CD32) and Mac-1 (CD11b/CD18) for EnhancedEffector Cell Adhesion and Azurophil Granule Exocytosis," Blood, 99(11):4166-73.
|Miyake et al., (1988), "Synthesis of Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator Variants Resistant to Plasmin and Thrombin," J. Biochem., 104:643-647.
|Mosmann et al., (1989), "TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," Ann. Rev. Immunol. vol. 7, pp. 145-173.
|Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," J. Mol. Biol., 247:979-994.
|Mueller et al. (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," Molecular Immunology, 34(6):441-452.
|Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," J. Immunology, 144(4):1382-1386.
|Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," Proc. Natl. Acad. Sci. USA., 87:5702-5705.
|Mullins et al. (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," Cancer Immunol. Immunother, 45:20-28.
|Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," Immunopharmacol. Immunotoxicol., 20:473-492.
|Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diptheria toxin-related alpha-melanocyte-stimulating hormone fusion protein," Proc. Natl. Acad. Sci. USA, vol. 83, pp. 8258-8262.
|Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diptheria toxin-related α-melanocyte-stimulating hormone fusion protein," Proc. Natl. Acad. Sci. USA, vol. 83, pp. 8258-8262.
|Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach t chimeric toxin development," Immunotoxins, pp. 123-140.
|Naramura et al., "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein against Human Melanoma Cells," Immunology Letters, 39(1):91-9, (2003 ).
|Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," Cancer Immuno. Immunother., 37:343-349.
|Nastala et al., (1994), "Recombinant IL-12 Administration Induces Tumor Regression in Association with IFN-γ Production," J. Immunol., 153:1697-706.
|Neal et al. (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," Cancer Immunol Immunother., 53:41-52.
|Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," Nucleic Acids Research, vol. 13, No. 17, pp. 6363-6373.
|Neithammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Murine Melanoma," Cancer Res., 61(16):6178-84.
|Nelles et al., (1987), "Characterization of Recombinant Human Single Chain Urokinase-Type Plaminogen Activtor Mutants Produced by Site-Specific Mutagenesis of Lysine 158," J. Biol. Chem., 262(12):5682-5689.
|Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," Cancer Research, 55:5451-5458.
|Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," Proc. Nat. Acad. Sci., 96:3137-3142.
|Neuberger, et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions.," Nature, vol. 312, pp. 604-608.
|Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), pp. 433-440 and 492-495, Birkhauser, Boston, MA.
|Ngo et al., (1994), "The Protein Folding Problem and Tertiary Structure Prediction," pp. 433-440 and 492-495, Birkhauser Boston.
|Niethammer et al., (2002) "An oral DNA Vaccine against Human Carcinembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," Vaccine, 20:421-9.
|Nimtz et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells, Eur. J. Biochem., 213:39-56.
|O'Reilly et al., (1994), "Angiostatin: a Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, vol. 79, pp. 315-328.
|O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," Nature Medicine, vol. 2, No. 6, pp. 689-692.
|O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell, vol. 88 pp. 277-285.
|Orlandi et al., (1989), "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," Proc. Natl. Acad. Sci. USA, 86:3833-7.
|Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," Cancer Immunol. Immunother., 42(2):88-92.
|Park et al., (2000), "Efficiency of Promoter and Cell line in High-level Expression of Erythropoietin," Biotechnol. Appl. Biochem., 32:167-172.
|Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins", Journal of Biological Chemistry, vol. 264, No. 26, pp. 15157-15160.
|Paul et al., (1988), "Lymphotoxin," Ann. Rev. Immunol., vol. 6, pp. 407-438.
|Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," J. Exp. Medicine, vol. 163, pp. 166-178.
|Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," Journal Immunology, vol. 142, No. 10, pp. 3662-3667.
|Pertl et al., (2003), "Immunotherapy with a Posttranscriptionally Modified DNA Vaccine Induces Complete Protection Against Metastatic Neuroblastoma," Blood, 101(2):649-654.
|Perussia et al., (1992), "Natural Killer (NK) Cell Stimulatory Factor of IL-12 Has Differential Effects of the Proliferation of TCR-αβ+, TCR-γδ+ T Lymphocytes, and NK Cells," J. Immunol., 149:3495-502.
|Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," Cancer Res., 59:1036-1040.
|Putzer et al. (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," Proc. Nat'l Acad. Sci., vol. 94, pp. 10889-10894.
|Queen et al., (1989), "A Humanized Antibody that Binds to the Interleukin 2 Receptor," Proc. Natl. Acad. Sci. USA, 86:10029-33.
|Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," Prog. Brain Res., 101:201-212.
|Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," J Clin Lab Anal., 10(3)1 60-6.
|Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Mestastases in Athymic nu/nu Mice by an Antibody-lymphotoxin Fusion Protein," Cancer Res., 56(8):1707-12.
|Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," Current Topics in Microbiology and Immunolgy, pp. 27-53.
|Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," Melanoma Research, vol. 7. Suppl. 2, pp. S99-S106.
|Ricchmann et al., (1988), "Reshaping Human Antibodies for Therapy," Nature, 332:323-7.
|Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," The Lancet, vol. 343, pp. 1177-1183.
|Robinson et al., (1998), "Optimizing the Stability of Single-Chain Proteins by Linker Length and Composition Mutagenesis," Proc. Natl. Acad. Sci. USA, 95:5929-34.
|Roessler et al., (1994), "Cooperative Interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-bindign affinity of the receptor subunits," Proc. Natl. Acad. Sci., 91:3344-3347.
|Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," Immunology, Third Edition, 8.3-8.4.
|Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," Immunology Today, vol. 9, No. 2, pp. 58-62.
|Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," Structure 2, vol. 2, No. 3, pp. 159-173.
|Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Ssuppress Growth and Dissemination of Murine Colon Carcinoma," Cancer Res., 61(23):8498-503.
|Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," Proc. Natl. Acad. Sci. USA, 91(20):9626-30.
|Saleh et al., (1992), "Phase 1 Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," Hum. Antiob. Hybridomas, 3:19-24.
|Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α," J. Exp.Med., 179:1109-1118.
|Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," Cancer Research, vol. 46, pp. 4701-4705.
|Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," the Embo Journal, vol. 17, No. 15, pp. 4249-4256.
|Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the α chain (p55) of the interleukin 2 receptor," Proc. Natl. Acad. Sci., 88:4636-4640.
|Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in Molecular Foundations of Oncology, pp. 95-133.
|Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminiogen activator," Proc. Natl. Acad. Sci. USA, vol. 84, pp. 6904-6908.
|Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," Journal of Immunology, vol. 148, No. 11, pp. 3433-3340.
|Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," Journal of National Cancer Institute, 93:1204-1214.
|Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," Proc. Natl. Acad. Sci USA, vol. 85, No. 13, pp. 4842-4846.
|Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," Nature Biotechnology, 18:1197-1202.
|Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," J. Immunol., 163:50520-5028.
|Sharp et al., (1988), "Codon Usage Patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Shizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens; a Review of the Considerable Within-Species Diversity," Nucleic AcidsRes., 16(17):8207-8211.
|Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG mediates cytotoxicity by Human Monocytes that is enhanced by interferon γ and is not blocked by human IgG," Journal of Immunology,vol. 137, No. 11, pp. 3378-3382.
|Shiff et al., (1995), "Sulindac Sulfide, an Asprin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," Journal of Clinical Investigation, vol. 96, pp. 491-503.
|Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," Proc. Natl. Acad. Sci. USA, vol. 87, pp. 5322-5326.
|Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," J. Biol.Chem., 278:3466-3473.
|Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," Cancer Research, vol. 57, pp. 1329-1334.
|Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," J. Exp. Med., 196:303-310.
|Stevenson et al., (1997), "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab′γ and Analogous Ligands," Journal of Immunology, vol. 158, pp. 2242-2250.
|Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," Therapeutic Immunology, Blackwell Science, Chapter 36, pp. 451-456.
|Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," Adv. Cancer Res., 60:247-267.
|Syed et al., (1998), "Efficiency of Signaling through Cytokine Receptors Depends Critically on Receptor Orientation," Nature, 395:511-516.
|Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," Nature, vol. 302, pp. 305-309.
|Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrage in the Structure and Effector Functions Mediated by the Human IgG Constant Region," Journal of Immunology, vol. 143, No. 8, pp. 2595-2601.
|Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Copmlement Activation," Journal of Experimental Medicine, vol. 178, No. 2, pp. 661-667.
|Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," Int. J. Cancer, vol. 57, pp. 920-925.
|The Merck Manual of Diagnosis and Therapy, 990-993, 1278-1283 (17th ed..1999).
|Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," Mol. Immunol., 37(16):995-1004.
|Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," Cancer Research, vol. 48, No. 5, pp. 1119-1123.
|Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," Science, vol. 242, pp. 1166-1168.
|Tiruppathi et al., (1996), "Isolation and Characterization of a Cell Surface Albumin-Binding Protein from Vascular Endothelial Cells," Proc. Nat. Acad. Sci. USA, 93:250-4.
|Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," Blood, vol. 84, pp. 4008-4027.
|Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," Cancer Research, vol. 56, pp. 467-470.
|Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodes," Cancer Research, vol. 44, pp. 681-687.
|Verhoeyen et al.(1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science 239:1534-1536.
|Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," Blood, 90:12-20.
|Voest et al., (1995), "Inhibition of Angiogenesis in Vivo by Interleukin 12," J. Natl. Canc. Inst., 87:581-6.
|Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," Blood, 90:3662-3672.
|Weber et al., (2001), "Phase 1 Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: Clinical, PK, and Biological PD Results (Abstract)," American Society of Clinical Oncology Program/Proceedings, 20(Part 1):259a.
|Weitkamp et al., (1973), "Additional Data on the Population Distribution of Human Serum Albumin Genes; Three New Variants," Ann. Hum. Genet., 37:219-26.
|Wells, (1990), "Additivity of Mutational Effect in Proteins," Biochemistry, 29(37):8509-8517.
|Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," Blood, 82(5):1507-1516.
|Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," J. Biological Chemistry, 269(36):22839-22846.
|Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase 1 Klenow fragment," Gene, vol. 43, pp. 319-324.
|Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein", Protein Engineering, vol. 1, No. 6, pp. 493-498.
|Wooley et al. (1993) "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice," J. Immunol. 151: 6602-6607.
|Wu et al.,( Jul. 1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin", Biochemical and Biophysical Research Communications, vol. 236, No. 3, pp. 651-654.
|Wysocka et al., (1995), "Interleukin-12 is Required for Interferon-γ Production and Lethality in Lipopolysaccharide-Induced Shock in Mice," Eur. J. Immunol., 25:672-6.
|Xiang et al.(1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," Cancer Research, vol. 57, pp. 4948-4955.
|Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," Cancer Research, 58(17)3918-3925.
|Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absense of Antigen," J. Immunol., 163(7):3676-83.
|Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," J Immunol., 167(8):4560-5.
|Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," Clin Cancer Res., 7(3 Supp):S856-S864.
|Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," J. Biol. Chem., 269(5):3469-3474.
|Yan et al., (1996), "Characterization of an Ig VH Idiotope that Results in Specific Homophilic Binding and Increased Avidity for Antigen," J. Immunol., 157:1582-8.
|Yeh et al., (1992), "Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," Proc. Natl. Acad. Sci. USA, 89:1904-8.
|Yu et al., (1998), "Phase 1 Trial of a Human-Mouse Chimeric Anti-Disaloganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," J. Clin. Oncol., 16(6):2169-80.
|Zagozdzon et al. (1999), "Potentiation of Antitumor Effect of IL-12 in Combination with Paclitaxel in Murine Melanoma Model In Vivo," International Journal of Molecular Medicine, 4:645-648.
|Zheng, et al., (1995), "Administration of nonstyolytic IL-10/Fc in murine models of lipopolysaccaride-induced septic shock and allogenic islet transplantation." Journal Immunology, vol. 154, No. 10, pp. 5590-5600.
|U.S. Classification
|424/85.1, 424/178.1, 424/85.2
|International Classification
|Cooperative Classification
|European Classification
|Jul 30, 2010
Owner name: MERCK PATENT GMBH, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EMD LEXIGEN RESEARCH CENTER CORP.;REEL/FRAME:024768/0887
Effective date: 20071220
Owner name: EMD LEXIGEN RESEARCH CENTER CORP., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GILLIES, STEPHEN D.;LO, KIN-MING;LAN, YAN;REEL/FRAME:024768/0752
Effective date: 20031113
|Apr 5, 2011
|Certificate of correction
|Jul 2, 2014
|Fee payment
Year of fee payment: 4